pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,474 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1204Endpoints913BioPharma Dive352BioSpace332Fierce Biotech311onclive165raps110globenewswire health73
therapy area
allOncology7983Rare Disease1918Cardiology1857Immunology1533Hematology1346Vaccines1243Pulmonology
  • Experts highlight lack of reliable biomarkers for melanoma immunotherapy response
    Dr. Mario Sznol, a professor of clinical medical oncology at the University of Miami, discussed the ongoing difficulty of predicting which patients with metastatic melanoma will benefit from immune…
    onclive · 4mo agoNegative↗ source
  • Utah invests in AI supercomputer to boost health research and biotech innovation
    State of Utah announced a major investment in artificial intelligence and high-performance computing infrastructure aimed at accelerating health research. The new AI supercomputer, managed by the…
    onclive · 4mo agoPositive↗ source
← prev
page 92 of 99
next →
fda recalls71
fda medwatch61
fda press38
1239
Psychiatry & CNS882
Ophthalmology518
Pain498
Endocrinology & Metabolism490
Infectious Disease455
Expert Consensus Offers Guidance on Evolving Multiple Myeloma Treatment Strategies
A 2025 expert consensus presented at the Bridging the Gaps meeting highlighted how quickly multiple myeloma care is changing and gave clinicians practical advice for navigating expanding treatment…
onclive · 4mo agoNeutral↗ source
  • Experts outline PET-CT, biopsy and mutation testing to guide therapy in relapsed CLL
    In a recent discussion, clinicians described the workup for patients with progressive chronic lymphocytic leukemia (CLL). They emphasized using PET‑CT imaging and excisional lymph node biopsy when…
    onclive · 4mo agoNeutral↗ source
  • Experts discuss mutation testing and patient factors to guide second-line CLL therapy after BTK inhibitor resistance
    A 66-year-old man who was diagnosed with chronic lymphocytic leukemia five years ago and initially had an unmutated IGHV profile without TP53 alteration has been on continuous covalent BTK inhibito…
    onclive · 4mo agoNeutral↗ source
  • Daraxonrasib uniquely targets active KRAS in pancreatic cancer, says MD Anderson expert
    Dr Shubham Pant, a professor in the Department of Gastrointestinal Medical Oncology at MD Anderson Cancer Center, explained the mechanism of daraxonrasib in a recent commentary. The oral, potent R…
    onclive · 4mo agoPositive↗ source
  • CellCentric secures $220 million Series D to advance oral multiple myeloma drug inobrodib
    CellCentric, a biotech focused on multiple myeloma, announced a $220 million Series D financing led by Venrock. The capital will fund ongoing Phase 2 trials and a planned Phase 3 study of its oral…
    BioPharma Dive · 4mo agoDealPositive↗ source
  • Sanofi requests removal of teplizumab from FDA fast-track voucher program after director dispute
    Sanofi has formally asked the Food and Drug Administration to withdraw its type 1 diabetes therapy, teplizumab, from the new speedy review voucher program overseen by Commissioner Marty Makary. Th…
    STAT · 4mo agoRegulatoryNegative↗ source
  • Bayer to buy Perfuse for up to $2.45B, bolstering eye drug pipeline
    Centered around a glaucoma therapy in mid-stage testing, the deal is Bayer’s first drug company acquisition in several years and potentially its largest since it purchased AskBio in 2020.
    BioPharma Dive · 4mo agoDealNeutral↗ source
  • Color Health expands into cancer treatment coordination with virtual tumor boards
    Color Health, a telehealth firm that currently coordinates cancer screening, is moving into providing and coordinating actual cancer care services. CEO Othman Laraki says the growing complexity of…
    STAT · 4mo agoPositive↗ source
  • FDA authorizes fruit-flavored vapes amid political pressure, sparking debate over youth risk and quitting aid
    The U.S. Food and Drug Administration granted its first authorization for fruit-flavored e-cigarettes on Tuesday, adding mango- and blueberry-tasting products from Los Angeles-based Glas to its app…
    STAT · 4mo agoRegulatoryNeutral↗ source
  • Experts preview top HR+ and HER2+ breast cancer abstracts ahead of ASCO 2026
    Preparations are under way for the 2026 ASCO Annual Meeting, and breast cancer updates are generating strong interest among clinicians. Leading oncologists including Dr. Yara Abdou of UNC, Dr. VK…
    onclive · 4mo agoNeutral↗ source
  • PhRMA launches seven-figure ad campaign against 340B drug discount program
    PhRMA, the leading pharmaceutical lobbying group, announced a new advertising push aimed at the federal 340B drug discount program. The campaign, described as a seven-figure effort, is set to begi…
    STAT · 4mo agoRegulatoryNeutral↗ source
  • Phase 3 MANEUVER trial shows pimicotinib improves response and pain in advanced TGCT, supporting FDA NDA acceptance
    The phase 3 MANEUVER study evaluated pimicotinib in patients with advanced diffuse tenosynovial giant cell tumor. The trial compared the oral agent to placebo and collected both clinical and patien…
    onclive · 4mo agoPositive readoutPositive↗ source
  • STAT+: How a global effort to explore the ‘dark proteome’ is upending our understanding of human disease
    An international team has found thousands of mini-proteins, including some involved in cell division and DNA repair, as well as several unique to cancer cells.
    STAT · 4mo agoRegulatoryNeutral↗ source
  • Health AI progress limited by bad data, newsletter notes
    The latest AI Prognosis newsletter highlights that the quality of health data is a major obstacle for building useful AI tools in medicine. The author explains that many existing datasets contain…
    STAT · 4mo agoNeutral↗ source
  • Higher PD-L1 levels linked to poorer outcomes in EGFR-mutated NSCLC treated with first-line osimertinib
    Dr. Jonathan Wennan Lee, a chief hematology/oncology fellow at Weill Cornell Medicine, discussed the emerging role of PD-L1 as a predictive biomarker for first-line osimertinib resistance in EGFR-m…
    onclive · 4mo agoNegative readoutNeutral↗ source
  • Experts discuss next-generation pathology and precision care for non-small cell lung cancer in new CME podcast
    The CME podcast released on May 6, 2026 brings together Sanja Dacic, Isabel Preeshagul, and Soo-Ryum (Stewart) Yang to review recent advances in pathology for non-small cell lung cancer. The exper…
    onclive · 4mo agoNeutral↗ source
  • HHS focuses on overmedication as cruise ship hantavirus outbreak prompts port change
    The Health and Human Services department announced new efforts to curb excessive prescribing, highlighting concerns about overmedication in the United States. At the same time, a cruise ship ancho…
    STAT · 4mo agoNeutral↗ source
  • OpenAI’s health AI policy blueprint seen as reasonable yet self‑serving, experts say
    OpenAI has expanded its health‑focused AI tools, rolling out ChatGPT Health for consumers, a hospital‑oriented ChatGPT for Healthcare, and a version for clinicians. Alongside the clinician chatbot,…
    STAT · 4mo agoRegulatoryNegative↗ source
  • PeaceHealth abandons plan to outsource Oregon emergency doctors to ApolloMD after lawsuit and local opposition
    PeaceHealth, a nonprofit health system in Oregon, announced Wednesday that it will not move its emergency department staffing to the national physician staffing firm ApolloMD. The decision reverse…
    STAT · 4mo agoRegulatoryNeutral↗ source
  • Dr McGregor on the DAD-IO Trial of Sacituzumab Govitecan and EV in Metastatic Urothelial Carcinoma
    Bradley McGregor, MD, discusses the background and design of the phase 1/2 DAD-IO trial in metastatic urothelial carcinoma.
    onclive · 4mo agoNeutral↗ source
  • Dementia care faces ambiguous loss, a unique grief that strains relationships
    Jason Karlawish, a professor of medicine and neurology at the University of Pennsylvania, wrote an opinion piece on the concept of ambiguous loss in dementia care. He reflects on a recent interview…
    STAT · 4mo agoNeutral↗ source
  • Dr. Glaucomflecken protests corporate staffing of PeaceHealth emergency department in Oregon
    Dr. Glaucomflecken, the online persona of physician Will Flanary, hosts the First Opinion Podcast where he blends humor with health‑care commentary. He has become a vocal critic of PeaceHealth’s p…
    STAT · 4mo agoNegative↗ source
  • Iopofosine I-131 shows high response rates and durable disease control in Waldenstrom macroglobulinemia trial
    The 12‑month follow‑up from the CLOVER‑WaM study reports that patients receiving Iopofosine I‑131 achieved strong clinical activity in Waldenstrom macroglobulinemia. In the per‑protocol group, the…
    onclive · 4mo agoPositive readoutPositive↗ source